AUPH EBITDA Growth
Aurinia Pharmaceuticals Inc · EBITDA Growth
AUPH EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported117.60%period ending
AUPH TTM EBITDA YoY % (-521.93% → 117.60%)
Year-over-year change
High-resolution chart · PNG
AUPH ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 117.5958% | |
| 145.5753% | |
| 348.5124% | |
| 2,232.9613% | |
| 475.9965% | |
| 257.3291% | |
| 150.3244% | |
| 106.469% | |
| 66.4655% | |
| 54.4437% | |
| 39.1708% | |
| 38.632% | |
| 55.1149% | |
| 44.0605% | |
| 41.6605% | |
| 28.7992% | |
| -3.408% | |
| -28.345% | |
| -72.9135% | |
| 8.1967% | |
| -1.3578% | |
| 5.1238% | |
| 15.8621% | |
| -179.9414% | |
| -144.038% | |
| -126.5348% | |
| -94.994% | |
| 0.3003% | |
| -6.4945% | |
| -17.9918% | |
| -37.3114% | |
| -47.9497% | |
| -72.272% | |
| -86.4392% | |
| -113.7708% | |
| -84.3668% | |
| -40.4606% | |
| -9.6719% | |
| 16.0304% | |
| -3.9869% | |
| -21.0672% | |
| -39.9581% | |
| -60.7389% | |
| -76.7961% | |
| -69.1009% | |
| -120.5849% | |
| -196.4346% | |
| -26.9146% | |
| -41.9127% | |
| 9.4518% | |
| 36.4643% | |
| -867.5409% | |
| -1,956.5402% | |
| -237.1643% | |
| -263.6611% | |
| -319.2655% | |
| -332.327% | |
| 224.5039% | |
| 218.9031% | |
| 113.0334% | |
| 104.3054% | |
| 13.1535% | |
| 44.3523% | |
| 52.5894% | |
| 57.4966% | |
| 50.6278% | |
| 46.2425% | |
| 67.1003% | |
| 65.4273% | |
| 60.5619% | |
| 55.5612% | |
| 25.6112% | |
| 6.0611% | |
| -24.7512% | |
| -45.2723% | |
| -16.7049% | |
| -9.366% | |
| 7.3874% | |
| 22.7035% | |
| 8.9962% | |
| 7.1986% | |
| -8.4588% | |
| -40.9632% | |
| -61.3838% | |
| -85.4139% | |
| -155.0287% | |
| -115.0465% | |
| -130.0707% | |
| -705.2426% | |
| -557.9325% | |
| -1,193.4078% | |
| -2,843.6249% | |
| 64.9368% | |
| 85.4518% | |
| 97.5011% | |
| 43.4204% | |
| -27.6006% | |
| -136.0022% | |
| -221.2017% | |
| -375.5473% |